Seres Therapeutics Inc (MCRB)

  • Get an in-depth profile of Seres Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
4.73 +0.06 (+1.28%)
Closed USD Disclaimer
4.79 +0.06 (+1.27%)

Seres Therapeutics Inc Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
333
Equity Type
ORD
Seres Therapeutics, Inc. is a microbiome therapeutics company. The Company is developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead product candidate, SER-109, is designed to reduce further recurrence of CDI, a debilitating infection of the colon, in patients who have received antibiotic therapy for recurrent CDI by restructuring the gastrointestinal microbiome and modulating the metabolic landscape to address CDI. Building upon SER-109, it is developing microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and GvHD in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Contact Information
Address
Cambridge,02139 United States
Phone
617 945 9626
Fax
-
Web
https://www.serestherapeutics.com
Top Executives
Name
Age
Since
Title
Richard N. Kender 65 2014 Independent Director
Eric D. Shaff 45 2014 President, CEO & Director
Gregory Behar 52 2014 Independent Director
Mark Wilcox 0 2015 Member of Scientific Advisory Board
Dennis Arthur Ausiello 75 2015 Independent Director
Stephen A. Berenson 60 2019 Independent Chairman
Kurt C. Graves 53 2015 Independent Director
Curtis Huttenhower 0 0000 Member of Scientific Advisory Board
Andrew Goodman 0 0000 Member of Scientific Advisory Board
Willard H. Dere 68 2017 Independent Director
Meryl S. Zausner 65 2018 Independent Director
Paul R. Biondi 53 2020 Independent Director
Marcel van den Brink 0 0000 Member of Scientific Advisory Board
Elhanan Borenstein 0 0000 Member of Scientific Advisory Board
Robert Jenq 0 0000 Member of Scientific Advisory Board
Claire M. Fraser-Liggett 68 2023 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.